Investigation of anti-cholinesterase and anti-amyloidogenic activities of beta-lactam antibiotics

dc.contributor.authorOzer, Eda Ozturan
dc.contributor.authorMirza, Hasan Cenk
dc.contributor.authorTan, Oya Unsal
dc.contributor.authorTurkoglu, Suna
dc.contributor.orcID0000-0002-8853-3893en_US
dc.contributor.orcID0000-0003-4805-1918en_US
dc.contributor.researcherIDF-1232-2015en_US
dc.contributor.researcherIDAAJ-2243-2021en_US
dc.date.accessioned2022-12-12T10:52:59Z
dc.date.available2022-12-12T10:52:59Z
dc.date.issued2022
dc.description.abstractObjectives: Neuroinflammation is an important factor in the pathogenesis of neurodegenerative disesases. The following study aimed to clarify the effects of beta-lactam antibiotics to the cholinergic system, on acetylcholinesterase (AChE), butyrylcholinesterase (BuChE) activities, considering the structural differences of antibiotics, to evaluate the underlying mechanism of effects provided by protein-antibiotic interactions, and to clarify possible effects of the antibiotics on the aggregation of A beta-peptides. Methods: The inhibition/activation mechanisms for each antibiotic were examined kinetically by Ellman method. Destabilization effects of them on amyloid peptide fibrillation were examined and protein-ligand interactions were evaluated with most potent antibiotics by molecular docking studies. Results: The most powerful inhibitions were detected by the inhibition studies of AChE with ceftazidime (CAZ) and BuChE with amoxicillin (AMX). CAZ was exhibited dose-related dual effect on AChE activity. CAZ was actually the dose-related modifier of AChE. At higher concentrations, CAZ was a nonessential activator of AChE. Molecular docking studies have been confirmed by kinetic studies. Interested beta-lactam antibiotics did not prevent fibrillation rate as rifampicin. Conclusion: Inhibition/activation behaviours of studied beta-lactam antibiotics on both cholinesterases may suggest that cholinergic transmission is one of the crucially important components of the beta-lactam antibiotics-induced central nervous system adverse reactions.en_US
dc.identifier.endpage369en_US
dc.identifier.issn0250-4685en_US
dc.identifier.issue3en_US
dc.identifier.scopus2-s2.0-85130893000en_US
dc.identifier.startpage359en_US
dc.identifier.urihttps://www.degruyter.com/document/doi/10.1515/tjb-2021-0277/html
dc.identifier.urihttp://hdl.handle.net/11727/8266
dc.identifier.volume47en_US
dc.identifier.wos000798124300001en_US
dc.language.isoengen_US
dc.relation.isversionof10.1515/tjb-2021-0277en_US
dc.relation.journalTURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISIen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergien_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectbeta-lactam antibioticsen_US
dc.subjectacetylcholinesteraseen_US
dc.subjectamyloid beta peptidesen_US
dc.subjectbutyrylcholinesteraseen_US
dc.subjectmolecular dockingen_US
dc.titleInvestigation of anti-cholinesterase and anti-amyloidogenic activities of beta-lactam antibioticsen_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
10.1515_tjb-2021-0277.pdf
Size:
1.57 MB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: